SCHEMBL264423

SCHEMBL264423

CCOc1ccc(F)cc1-c1ccc(NC(=O)c2conc2C)nc1N

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 9/20 0.62
SCN5A Q14524 1/20 0.62
SCN9A Q15858 1/20 0.62
SCN2A Q99250 1/20 0.62
SCN3A Q9NY46 1/20 0.62
CSNK1D P48730 3/20 0.39
CSNK1E P49674 3/20 0.39
PPARG P37231 1/20 0.39
NCOA2 Q15596 1/20 0.39
NCOA1 Q15788 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
MRGPRX1 Q96LB2 4/20 0.38
PDE10A Q9Y233 1/20 0.36
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263586 0.93 SCN10A (0.60) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL14237394 0.91 SCN10A (0.60) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL14237564 0.90 SCN10A (0.59) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL263374 0.90 SCN10A (0.64) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL14237596 0.90 SCN10A (0.65) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL14237594 0.88 SCN10A (0.57) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL262879 0.88 SCN10A (0.60) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL14237465 0.87 SCN10A (0.62) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL263316 0.87 SCN10A (0.81) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL14237608 0.86 SCN10A (0.67) SCN10ASCN5ASCN9ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885SCN5A 157/4885SCN9A 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.